Amarin Corporation plc
http://www.amarincorp.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amarin Corporation plc
Stock Watch: Why Have All The Buyouts Gone?
Clinical trial results that readily excite stock market investors are subject to more stringent analysis by big pharma deal-hunters, despite their urgent need for pipeline renewal.
Deal Watch: Vanda Gets Competing Offer From Cycle After Unsolicited Future Pak Bid
Plus deals involving GSK/Elsie, Lilly/QurAlis, Gilead/Cartography as well as tech transfer announcements and deals in brief.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Amarin Pharma
- Amarin Pharmaceuticals Ireland Limited
- Laxdale Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice